Search results
Results from the WOW.Com Content Network
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
The safety and efficacy of crisaborole were established in two placebo-controlled trials with a total of 1,522 participants ranging in age from two years of age to 79 years of age, with mild to moderate atopic dermatitis. [1] In both trials participants received treatment with either crisaborole or placebo twice daily for 28 days. [16]
Crisaborole (AN2728), a boron-containing drug for the topical treatment of psoriasis and atopic dermatitis. [ 24 ] [ 25 ] It was approved by the FDA on December 14, 2016 under the brand name Eucrisa for the treatment of mild-to-moderate atopic dermatitis (eczema) in patients 2 years of age and older.
Peripheral neuropathy and mononeuropathy are common neurological disorders, with a diverse range of variables and causes to conclude a diagnosis. [2] Neuropathy has three sub-classifications; mononeuropathy is a result of an entrapped or traumatised nerve or nerve area, Mononeuropathy multiplex is linked to chronic diseases like leprosy, and ...
Parkinson's typically manifests in individuals over 60, with about one percent affected. In those younger than 50, it is termed "early-onset PD". No cure for Parkinson's is known, and treatment focuses on alleviating symptoms. Initial treatment typically includes L-DOPA, MAO-B inhibitors, or dopamine agonists.
Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process.
Treatment consists of three phases of immunotherapy: 1. Acute phase: IV steroids (methylprednisolone 1 mg/kg) for 3–5 days or plasmapheresis are given to restore visual function. [3] 2. Intermediate phase: Oral steroids (typically prednisone 1 mg/kg) with taper are given to stabilize vision. [3] 3.
There are three main types of synucleinopathy: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). [1] Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies. [2]